

SEARCH REQUEST FORM

Access DB#

SEARCHED

Scientific and Technical Information Center APR 18 2003

Requester's Full Name: MOLLY CEPERLEY Examiner #: 59757 Date: 04/18/03
 Art Unit: 1641 Phone Number 308-4239 Serial Number: 041923760
 (Mail Box and Bldg/Room Location): CM1-8D15 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.


Title of Invention: _____

Inventors (please provide full names): _____


Earliest Priority Filing Date: _____

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

① Please search for



② Please search for



(In trying to search a species of claims 36-39 (attached).
 Additional terms: protein chips, gold, immobilizⁿ, capture polypeptide,
 fusion protein, alkane thiolate phosphonate, polyethylene glycol
 (also see figure 13 attached.)

STAFF USE ONLY

Searcher: POINT OF CONTACT:

Searcher Phone #: PAUL SCHULWITZ

Searcher Location: TECHNICAL INFO. SPECIALIST

Date Searcher Picked Up: 4/18

Date Completed: 4/18

Searcher Prep & Review Time: 10

Clerical Prep Time: 12

Online Time: _____

Type of Search

NA Sequence (#) _____

AA Sequence (#) _____

Structure (#) 2

Bibliographic _____

Litigation _____

Fulltext _____

Patent Family _____

Other _____

Vendors and cost where applicable

STN 349,36

Dialog _____

Questel/Orbit _____

Dr.Link _____

Lexis/Nexis _____

Sequence Systems _____

WWW/Internet _____

Other (specify) _____


Part 1

Flood 10/291,570

April 18, 2003

=> d que

L1 STR



*Considered 05/27/03
Mgc*

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 1
CONNECT IS E1 RC AT 6
CONNECT IS E1 RC AT 8
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY UNS AT 4
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS E6 C AT 4

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 8

STEREO ATTRIBUTES: NONE

L3 111 SEA FILE=REGISTRY SSS FUL L1
L4 1 SEA FILE=REGISTRY ABB=ON PLU=ON CUTINASE/CN
L5 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L3 AND (L4 OR CUTINAS?)

=> d ibib abs hitstr 1-2

L5 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2003:173839 HCAPLUS

DOCUMENT NUMBER: 138:217877

TITLE: Immobilization of biological molecules onto surfaces
coated with monolayers

INVENTOR(S): Hodneland, Christian; Campbell, Stewart; Duffy, David;
Agosto, Melina; Wang, Evelyn

PATENT ASSIGNEE(S): Surface Logix, Inc., USA

SOURCE: PCT Int. Appl., 234 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003018854	A2	20030306	WO 2002-US27195	20020827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				

PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2001-315261P P 20010827
 US 2001-315544P P 20010828
 US 2002-356765P P 20020215
 US 2002-358412P P 20020215
 US 2002-357136P P 20020219
 US 2002-375023P P 20020220
 US 2002-380259P P 20020426

AB The present invention provides an article for immobilizing functional org. biomols. through a covalent bond to a thiolate monolayer on a coinage metal surface. Also provided are methods for making the article and methods for the immobilization of functional org. biomols. on the article. The thiolate monolayer contains two moieties, one having an inert group that is resistant to reacting with biomols. and one having a covalent bond forming group that reacts with the functional org. biomol. to covalently immobilize it on the monolayer.

IT **51377-41-4, Cutinase**

RL: ARU (Analytical role, unclassified); ANST (Analytical study)
 (immobilization of biol. mols. onto surfaces coated with monolayers)

RN 51377-41-4 HCAPLUS

CN Cutinase (9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **496837-08-2P**

RL: ARU (Analytical role, unclassified); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation)
 (immobilization of biol. mols. onto surfaces coated with monolayers)

RN 496837-08-2 HCAPLUS

CN Phosphonic acid, 7-octenyl-, ethyl 4-nitrophenyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:316564 HCAPLUS

DOCUMENT NUMBER: 137:43427

TITLE: Selective immobilization of proteins to self-assembled monolayers presenting active site-directed capture ligands

AUTHOR(S): Hodneland, Christian D.; Lee, Young-Sam; Min, Dal-Hee; Mrksich, Milan

CORPORATE SOURCE: Department of Chemistry, University of Chicago, Chicago, IL, 60637, USA

SOURCE: Proceedings of the National Academy of Sciences of the United States of America (2002), 99(8), 5048-5052

CODEN: PNASA6; ISSN: 0027-8424
 PUBLISHER: National Academy of Sciences
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 137:43427

AB This paper describes a method for the selective and covalent immobilization of proteins to surfaces with control over the d. and orientation of the protein. The strategy is based on binding of the serine esterase **cutinase** to a self-assembled monolayer presenting a phosphonate ligand and the subsequent displacement reaction that covalently binds the ligand to the enzyme active site. Surface plasmon resonance (SPR) spectroscopy showed that **cutinase** binds irreversibly to a monolayer presenting the capture ligand at a d. of 18 mixed among ~~tri(ethylene glycol)~~ groups. The covalent immobilization is ~~specific for cutinase~~ and the glycol-terminated monolayer effectively prevents unwanted nonspecific adsorption of proteins. To demonstrate that the method could be used to immobilize proteins of interest, a **cutinase**-calmodulin fusion protein was constructed and immobilized to the monolayer. SPR showed that calcineurin selectively assocd. with the immobilized calmodulin. This capture ligand immobilization method combines the advantages that the immobilization method combines the advantages that the immobilization reaction is highly selective for the intended protein, the tether is covalent and, hence, stable, and the method avoids the need for synthetic modification and rigorous purifn. of proteins before immobilization. These characteristics make the method well suited to a range of applications and, in particular, for constructing protein microarrays.


IT 3015-74-5 51377-41-4, **Cutinase**

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(selective immobilization of **cutinase** protein to self-assembled monolayers presenting active site-directed capture ligands)

RN 3015-74-5 HCAPLUS

CN Phosphonic acid, butyl-, ethyl 4-nitrophenyl ester (9CI) (CA INDEX NAME)



RN 51377-41-4 HCAPLUS

CN Cutinase (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Part 2


Flood 10/291,570

April 18, 2003

=> d que

L6

STR



Considered
05/23/03
mcc

NODE ATTRIBUTES:

CONNECT IS E2 RC AT 1
CONNECT IS E1 RC AT 6
CONNECT IS E1 RC AT 8
CONNECT IS E2 RC AT 11
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY UNS AT 4
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS E6 C AT 4

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

L8 3 SEA FILE=REGISTRY SSS FUL L6
L9 3 SEA FILE=HCAPLUS ABB=ON PLU=ON L8

=> d ibib abs hitstr 19 1-3

L9 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:316564 HCAPLUS

DOCUMENT NUMBER: 137:43427

TITLE: Selective immobilization of proteins to self-assembled monolayers presenting active site-directed capture ligands

AUTHOR(S): Hodneland, Christian D.; Lee, Young-Sam; Min, Dal-Hee; Mrksich, Milan

CORPORATE SOURCE: Department of Chemistry, University of Chicago, Chicago, IL, 60637, USA

SOURCE: Proceedings of the National Academy of Sciences of the United States of America (2002), 99(8), 5048-5052
CODEN: PNASA6; ISSN: 0027-8424

PUBLISHER: National Academy of Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 137:43427

AB This paper describes a method for the selective and covalent immobilization of proteins to surfaces with control over the d. and orientation of the protein. The strategy is based on binding of the serine esterase cutinase to a self-assembled monolayer presenting a phosphonate ligand and the subsequent displacement reaction that

covalently binds the ligand to the enzyme active site. Surface plasmon resonance (SPR) spectroscopy showed that cutinase binds irreversibly to a monolayer presenting the capture ligand at a d. of 1% mixed among tri(ethylene glycol) groups. The covalent immobilization is specific for cutinase, and the glycol-terminated monolayer effectively prevents unwanted nonspecific adsorption of proteins. To demonstrate that the method could be used to immobilize proteins of interest, a cutinase-calmodulin fusion protein was constructed and immobilized to the monolayer. SPR showed that calcineurin selectively assocd. with the immobilized calmodulin. This capture ligand immobilization method combines the advantages that the immobilization method combines the advantages that the immobilization reaction is highly selective for the intended protein, the tether is covalent and, hence, stable, and the method avoids the need for synthetic modification and rigorous purifn. of proteins before immobilization. These characteristics make the method well suited to a range of applications and, in particular, for constructing protein microarrays.


IT 438619-39-7P

RL: BUU (Biological use, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(selective immobilization of cutinase protein to self-assembled monolayers presenting active site-directed capture ligands)


RN 438619-39-7 HCAPLUS

CN 5,8,11,36,39,42-Hexaoxa-23,24-dithia-2-azatetratetracontanoic acid,
44-hydroxy-, 11-[ethoxy(4-nitrophenoxy)phosphinyl]undecyl ester (9CI) (CA
INDEX NAME)


PAGE 1-A



PAGE 1-B



PAGE 1-C



REFERENCE COUNT:


24

THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L9 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: (2000:595532 HCAPLUS
 DOCUMENT NUMBER: 133:346371
 TITLE: Design and synthesis of triglyceride analogue
 biotinylated suicide inhibitors for directed molecular
 evolution of lipolytic enzymes
 AUTHOR(S): (Deussen, H.-J.; Danielsen, S.; Breinholt, J.;
 Borchert, T. V.
 CORPORATE SOURCE: Protein Discovery, Novo Nordisk A/S, Bagsvaerd, 2880,
 Den.
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2000),
 10(17), 2027-2031
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 133:346371
 AB The design, synthesis, and inhibition properties of two new triglyceride
 analog biotinylated suicide inhibitors for directed mol. evolution of
 lipolytic enzymes by phage-display is described.
 IT **305368-27-8P**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (design and synthesis of triglyceride analog biotinylated suicide
 inhibitors for directed mol. evolution of lipolytic enzymes)
 RN 305368-27-8 HCAPLUS
 CN 5,6-Dithia-2,9,16-triazaheneicosanoic acid, 21-[(3aS,4S,6aR)-hexahydro-2-
 oxo-1H-thieno[3,4-d]imidazol-4-yl]-10,17-dioxo-, 11-[[2-
 decyltetradecyl)oxy](4-nitrophenoxy)phosphinyl]undecyl ester (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:157038 HCAPLUS

DOCUMENT NUMBER: 132:331229

TITLE: A novel biotinylated suicide inhibitor for directed molecular evolution of lipolytic enzymes

AUTHOR(S): Deussen, H.-J.; Danielsen, S.; Breinholt, J.; Borchert, T. V.

CORPORATE SOURCE: Protein Discovery, Novo Nordisk A/S, Bagsvaerd, Den.

SOURCE: Bioorganic & Medicinal Chemistry (2000), 8(3), 507-513
CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A bifunctional activity label for directed mol. evolution of lipolytic enzymes has been designed and synthesized. The structure is composed of a 4-nitrophenyl activated phosphonate connected to a biotin moiety through a disulfide bridge-contg. spacer. The phosphonate was prepd. by Michaelis-Arbuzov reaction of trimethylsilyl-protected 11-bromoundecanol with tri-Et phosphite. The deprotected .omega.-hydroxyalkylphosphonate was transformed into an active N-hydroxysuccinimide carbonate followed by 4-nitrophenyl activation of the phosphonate using std. procedures. The biotinylated phosphonate inhibitor was then synthesized by coupling the phosphonate inhibitor to a .epsilon.-amino-caproic acid-cystamine-contg. biotinyl spacer. The function of all relevant groups of the final activity label (biotin-label, cleavable disulfide bridge, phosphonate-inhibitor) have been successfully tested with the com. lipase Lipolase.RTM. (Novo Nordisk). Hence, a tool for directed mol. evolution of lipolytic enzymes has been developed.

IT 268227-44-7P

RL: NUU (Other use, unclassified); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)


(cleavable-biotinylated suicide inhibitor; purifn. and characterization of cleavable biotinylated suicide inhibitor suitable for directed mol. evolution of lipolytic enzymes).

RN 268227-44-7 HCAPLUS


CN 5,6-Dithia-2,9,16-triazaheneicosanoic acid, 21-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-10,17-dioxo-, 11-[ethoxy(4-nitrophenoxy)phosphinyl]undecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT:


28

THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d que

L6

STR



NODE ATTRIBUTES:

CONNECT IS E2 RC AT 1
 CONNECT IS E1 RC AT 6
 CONNECT IS E1 RC AT 8
 CONNECT IS E2 RC AT 11
 DEFAULT MLEVEL IS ATOM
 GGCAT IS MCY UNS AT 4
 DEFAULT ECLEVEL IS LIMITED
 ECOUNT IS E6 C AT 4

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE


L11 0 SEA FILE=MARPAT SSS FUL L6

Considered
05/23/03
MRC

=> d que

L6

STR



NODE ATTRIBUTES:

CONNECT IS E2 RC AT 1
 CONNECT IS E1 RC AT 6
 CONNECT IS E1 RC AT 8
 CONNECT IS E2 RC AT 11
 DEFAULT MLEVEL IS ATOM
 GGCAT IS MCY UNS AT 4
 DEFAULT ECLEVEL IS LIMITED
 ECOUNT IS E6 C AT 4

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE


L12 2 SEA FILE=BEILSTEIN SSS FUL L6

=> d qrd phy 112 1-2

L12 ANSWER 1 OF 2 BEILSTEIN COPYRIGHT 2003 BEILSTEIN CDS MDL

Beilstein Records (BRN): 8754793
 Chemical Name (CN): 2-decyltetradecyl (4-nitrophenyl)
 (11-<(2-<(2-<6-(5-<(3aR,4S,6aS)-2-oxoperhydrothieno<3,4-d>imidazol-4-yl>pentanoylamino)hexanoyl>aminoethyl)disulfanyl>ethylamino)carbonyl>oxyundecyl)phosphonate
 Autonom Name (AUN): <11-<2-(2-<6-<5-(2-oxo-hexahydrothieno<3,4-d>imidazol-6-yl)-pentanoylamino>-hexanoylamino>-ethyl)disulfanyl)-ethylcarbamoyloxy>-undecyl>-phosphonic acid
 2-decyl-tetradecyl ester 4-nitro-phenyl ester
 Molec. Formula (MF): C62 H111 N6 O10 P S3
 Molecular Weight (MW): 1227.75
 Lawson Number (LN): 32212, 5220, 3763, 3415, 3125, 1762, 385
 File Segment (FS): Stereo compound
 Compound Type (CTYPE): heterocyclic
 Constitution ID (CONSID): 7413634

Tautomer ID (TAUTID): 8238024
 Entry Date (DED): 2001/04/26
 Update Date (DUPD): 2001/04/26



Atom/Bond Notes:

1. CIP Descriptor: S
2. CIP Descriptor: R

Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	7
FS	File Segment	1
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
ED	Entry Date	1
UPD	Update Date	1
NMR	Nuclear Magnetic Resonance	1
PHARM	Pharmacological Data	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	1

RXPRO Substance is Reaction Product

1

Nuclear Magnetic Resonance:

NMR

Description (.KW): Chemical shifts
 Nucleus (.NUC): 1H
 Solvents (.SOL): CDCl3
 Frequency (.F): 400 MHz
 Reference(s):
 1. Deussen, H.-J.; Danielsen, S.; Breinholt, J.; Borchert, T. V.,
 Bioorg.Med.Chem.Lett., CODEN: BMCLE8, 10(17), <2000>, 2027 - 2032;
 BABS-6267564

L12 ANSWER 2 OF 2 BEILSTEIN COPYRIGHT 2003 BEILSTEIN CDS MDL

Beilstein Records (BRN): 8534896
 Chemical Name (CN): ethyl (4-nitrophenyl)(11-<(2-<(2-<6-(5-
 <(3aR,4R,6aS)-2-oxoperhydrothieno<3,4-
 d>imidazol-4-yl>pentanoylamino)hexanoyl>am
 inoethyl)disulfanyl>ethylamino)carbonyl>ox
 yundecyl)phosphonate
 Autonom Name (AUN): <11-<2-(2-<6-<5-(2-oxo-hexahydro-
 thieno<3,4-d>imidazol-6-yl)-
 pentanoylamino>-hexanoylamino>-
 ethyldisulfanyl)-ethylcarbamoyloxy>-
 undecyl>-phosphonic acid ethyl ester
 4-nitro-phenyl ester
 Molec. Formula (MF): C40 H67 N6 O10 P S3
 Molecular Weight (MW): 919.16
 Lawson Number (LN): 32212, 5220, 3763, 3415, 3125, 1762, 298
 File Segment (FS): Stereo compound
 Compound Type (CTYPE): heterocyclic
 Constitution ID (CONSID): 7235624
 Tautomer ID (TAUTID): 8037747
 Entry Date (DED): 2000/07/18
 Update Date (DUPD): 2000/07/18

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Atom/Bond Notes:

1. CIP Descriptor: S
2. CIP Descriptor: R

Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	7

FS	File Segment	1
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
ED	Entry Date	1
UPD	Update Date	1
MP	Melting Point	1
NMR	Nuclear Magnetic Resonance	5
PHARM	Pharmacological Data	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	1
RXPRO	Substance is Reaction Product	1

Melting Point:

Value	Ref.
(MP)	
(Cel)	
=====+=====	
127 - 132	1

Reference(s):

- Deussen, H.-J.; Danielsen, S.; Breinholt, J.; Borchert, T. V.,
Bioorg.Med.Chem., CODEN: BMECEP, 8(3), <2000>, 507 - 514; BABS-6222908

Nuclear Magnetic Resonance:

NMR

Coupling Nuclei (.NUI) 1H-1H,31P-1H

Reference(s):

- Deussen, H.-J.; Danielsen, S.; Breinholt, J.; Borchert, T. V.,
Bioorg.Med.Chem., CODEN: BMECEP, 8(3), <2000>, 507 - 514; BABS-6222908

NMR

Coupling Nuclei (.NUI) 31P-13C

Reference(s):

- Deussen, H.-J.; Danielsen, S.; Breinholt, J.; Borchert, T. V.,
Bioorg.Med.Chem., CODEN: BMECEP, 8(3), <2000>, 507 - 514; BABS-6222908

NMR

Description (.KW): Chemical shifts

Nucleus (.NUC): 31P

Solvents (.SOL): CDCl3

Frequency (.F): 162 MHz

Reference(s):

- Deussen, H.-J.; Danielsen, S.; Breinholt, J.; Borchert, T. V.,
Bioorg.Med.Chem., CODEN: BMECEP, 8(3), <2000>, 507 - 514; BABS-6222908

NMR

Description (.KW): Chemical shifts

Nucleus (.NUC): 1H

Reference(s):

- Deussen, H.-J.; Danielsen, S.; Breinholt, J.; Borchert, T. V.,
Bioorg.Med.Chem., CODEN: BMECEP, 8(3), <2000>, 507 - 514; BABS-6222908

NMR

Description (.KW):

Chemical shifts

Nucleus (.NUC):

¹³C

Reference(s):

1. Deussen, H.-J.; Danielsen, S.; Breinholt, J.; Borchert, T. V.,
Bioorg.Med.Chem., CODEN: BMECEP, 8(3), <2000>, 507 - 514; BABS-6222908